July 31 The benefits associated with Baxter International Inc's experimental treatment for certain diseases of the immune system outweigh the risks, an advisory committee to the U.S. Food and Drug Administration concluded on Thursday, paving the way for approval of the therapy.
The panel voted 15-1 that the available data show a favorable benefit to risk ratio for treatment, HyQvia, which is designed to treat primary immunodeficiency diseases.
These are genetic disorders in which certain cells of the immune system are missing, leading to a infections, recurrent pneumonia and abscesses of the organs.
The FDA is not obliged to follow the advice of its advisory panels but typically does so. (Reporting by Toni Clarke in Washington; Editing by Bill Trott)
GLOBAL MARKETS-European shares up as banks reassure, dollar holds near highs
LONDON, Oct 27 Reassuring results from some of Europe's biggest banks gave financials a boost on Thursday and helped offset weakness in oil-related stocks, while higher bond yields underpinned the dollar.
Moody's sees Russia's 2016 budget deficit at up to 4.7 pct of GDP
MOSCOW, Oct 27 Russia's budget deficit may reach 4.7 percent of gross domestic product this year if Moscow fails to sell a state stake in oil giant Rosneft, a senior vice president at Moody's Investor Service said on Thursday.